CPSE:GMAB
CPSE:GMABBiotechs

Is Genmab Still an Opportunity After 22% Surge and Antibody Pipeline Progress in 2025?

If you’re considering what your next move should be with Genmab stock, you’re not alone. The company has grabbed a lot of attention this year, and for good reason. After a period of underperformance, Genmab’s share price has not just rebounded but surged, climbing 9.3% over the last week and 22.6% in the past month. Year to date, holders are looking at a gain of 32.3%, while over the last twelve months, it has achieved a solid 27.6% return. That recent momentum stands in stark contrast to the...
CPSE:VWS
CPSE:VWSElectrical

Vestas (CPSE:VWS) Valuation in Focus After Major US and German Order Wins Signal Renewed Growth

The latest buzz around Vestas Wind Systems (CPSE:VWS) comes after it secured a string of substantial orders, including 320 MW in the USA and 42 MW in Germany. These new contracts point to growing confidence in Vestas’ project pipeline, reflecting a company that is turning renewed interest into tangible deals. Investors who have been following the stock know these wins arrive at a time when momentum and questions about the business’s long-term trajectory are front and center. In the bigger...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Examining Novo Nordisk’s Value After GLP-1 Supply News and Share Price Drop

Thinking about Novo Nordisk and wondering if now might be the right moment to act? You're definitely not alone. Whether you've been holding shares for years or are just considering diving in, the recent action in Novo Nordisk's stock price has been eye-catching. Over the last week, the stock has risen 4.3%, adding to a 2.9% climb over the past month. However, year-to-date performance is a stark contrast, with shares down 41.4%, and an even steeper 54.0% dip over the last year. That said,...
CPSE:ORSTED
CPSE:ORSTEDRenewable Energy

Does Ørsted’s Sharp 40% Share Fall Present an Opportunity for Investors in 2025?

If you are following Ørsted’s rollercoaster on the stock market, you are probably wondering what to do next. After all, it is not every day you see a company’s shares slide nearly 40% in a single week, or lose more than half their value over the last year. From soaring green energy hopes to the cold winds of shifting market sentiment, Ørsted has seen its fair share of drama. The recent sharp drops reflect a mix of investor anxiety about broader renewables funding, regulatory changes, and a...
CPSE:VWS
CPSE:VWSElectrical

3 European Stocks Estimated To Be Undervalued By Up To 36.7%

As European markets navigate a period of mixed performance, with the pan-European STOXX Europe 600 Index slightly lower and major stock indexes showing varied results, investors are keenly assessing monetary policy decisions and economic indicators. In this environment, identifying undervalued stocks becomes crucial as they can offer potential opportunities for growth despite broader market fluctuations.
CPSE:MAERSK B
CPSE:MAERSK BShipping

Maersk (CPSE:MAERSK B): How SmartKargo’s Integration Shapes the Latest Valuation Debate

If you’ve been watching A.P. Møller Mærsk (CPSE:MAERSK B) lately, you might have noticed a surge in conversation around the stock. What’s driving this renewed focus is Maersk’s announcement of successfully integrating SmartKargo’s advanced air cargo management system into its Own Controlled Air environment. This move promises real-time analytics, more transparency, and faster decision-making across air cargo operations, a shift that could materially enhance value for Maersk’s customers and...
CPSE:VWS
CPSE:VWSElectrical

Long-Term Deal for Rastede Wind Park Might Change the Case for Investing in Vestas (CPSE:VWS)

Vestas Wind Systems recently announced it has secured an order from Alterric Deutschland GmbH for the Rastede Wind Park in Germany, involving the delivery of seven V150-6.0MW turbines and a 25-year service agreement, with installation expected to start in the second quarter of 2026 and full commissioning by the fourth quarter of 2026. This order strengthens Vestas’s long-term service backlog and demonstrates continued demand for large-scale wind projects in the German market. We’ll now...
CPSE:HLUN B
CPSE:HLUN BPharmaceuticals

Is Lundbeck Still Attractive After 12.6% Monthly Surge and Positive Neurology Pipeline Updates?

If you are eyeing H. Lundbeck stock and trying to decide whether now is the right time to move, you are not alone. Investors have noticed the recent uptick, with shares climbing 5.6% in the past week and 12.6% over the last month. Year to date, the return is a solid 6.9%. What really stands out is the 91.1% gain over the past three years. Clearly, the market has warmed up to Lundbeck, giving some the sense that the momentum could continue, or perhaps that all the easy gains are already...
CPSE:ALK B
CPSE:ALK BPharmaceuticals

How Investors Are Reacting To ALK-Abelló (CPSE:ALK B) Expanding Dust Mite Allergy Franchise in China

ALK-Abelló recently announced a partnership with Changchun GeneScience Pharmaceutical Co. Ltd. (GenSci) to develop and commercialise its house dust mite allergy immunotherapy portfolio in Mainland China, granting GenSci exclusive rights until 2039 and transferring marketing, sales, and most clinical responsibilities to the local partner. This agreement aims to unlock significant potential in China’s under-tapped allergy immunotherapy market and allows ALK to reallocate resources to...